1. Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology's 68th Annual Scientific Session  GlobeNewswire
  2. Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™  PRNewswire
  3. Omega 3 fatty acid prescription pill lowers heart attack risk by 30%  Specialty Medical Dialogues
  4. View full coverage on Google News
“With this drug, we are not only preventing that first heart attack, but potentially the second stroke and maybe that third fatal event,” stated Deepak Bhatt, the study’s lead investigator.“With this drug, we are not only preventing that first heart attack, but potentially the second stroke and maybe that third fatal event,” stated Deepak Bhatt, the study’s lead investigator.

Amarin’s Vascepa Cuts Heart Attack and Stroke Risk by 30% | BioSpace

Taking a high dose of icosapent ethyl--a pure and stable prescription form of the omega-3 fatty acid known as EPA--significantly reduces the occurrence of first, subsequent and total ischemic events, including heart attacks, strokes and related deaths, among people at high cardiovascular risk despite already being on statin therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.Taking a high dose of icosapent ethyl--a pure and stable prescription form of the omega-3 fatty acid known as EPA--significantly reduces the occurrence of first, subsequent and total ischemic events, including heart attacks, strokes and related deaths, among people at high cardiovascular risk despite already being on statin therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Research: Pure omega-3 prescription drug significantly reduces the occurrence of ischemic events

Sucuri WebSite Firewall - Access Denied

“$AMRN Vascepa prevents second and third heart attacks in analysis, fueling debate https://t.co/1QOlyRjmu4 via @matthewherper, who is at #ACC19 for the data and spoke with a lot of cardiologists for their perspectives. Excellent read.”

Adam Feuerstein on Twitter: "$AMRN Vascepa prevents second and third heart attacks in analysis, fueling debate https://t.co/1QOlyRjmu4 via @matthewherper, who is at #ACC19 for the data and spoke with a lot of cardiologists for their perspectives. Excellent read."